**Claims:**

1. A compound of Formula (I):



Formula (I)

wherein:

$R^1$ is selected from hydrogen and $C_{1-4}$alkyl;

$R^2$ is selected from: $R^4$-C($R^{5a}R^{5b}$)- , $R^4$=C($R^6$)- and $R^{7a}$C($R^{7b}$)=C($R^6$)-;

$R^3$–X- is selected from methyl, methoxymethyl and



;

$R^4$ is selected from $C_{1-4}$alkyl, phenyl, $C_{3-6}$cycloalkyl and heteroaryl, wherein $R^4$ is optionally substituted by one or two substituents independently selected from $R^8$;

$R^{5a}$ and $R^{5b}$ are independently selected from hydrogen, fluoro and $C_{1-4}$alkyl;

$R^6$ is selected from hydrogen and $C_{1-4}$alkyl;

$R^{7a}$ and $R^{7b}$ are independently selected from $C_{1-4}$alkyl wherein $R^{7a}$ and $R^{7b}$ are optionally substituted by one or two substituents independently selected from $R^8$;

$R^8$ is independently selected from $C_{1-3}$alkyl, $C_{1-3}$alkoxy, fluoro and chloro;

with the proviso that:

(i) at least one of $R^{5a}$ and $R^{5b}$ is fluoro; and

(ii) when $R^2$ is $R^4$=C($R^6$)- then $R^4$ is $C_{3-6}$cycloalkyl;

or a salt, pro-drug or solvate thereof.

2. A compound of formula (I) as claimed in Claim 1, which is a compound of Formula (Ia)



Formula (Ia)

wherein:

$\mathbf{R^1}$ and $\mathbf{R^2}$ are as in claim 1;

or a salt, solvate or pro-drug thereof.

3. A compound of formula (I) as claimed in Claim 1, which is a compound of a compound of Formula (Ic)



Formula (Ic)

wherein:

$\mathbf{R^1}$ and $\mathbf{R^2}$ are as defined in Claim 1;

or a salt, solvate or pro-drug thereof.

4. A compound as claimed in any of claims 1 to 3, wherein $R^2$ is $R^4$-C($R^{5a}R^{5b}$)-, or a salt, solvate or pro-drug thereof.

5. A compound as claimed in any of claims 1 to 3, wherein $R^2$ is $R^4$=C($R^6$)-; or a salt, solvate or pro-drug thereof.

6. A compound of formula (I) as claimed in Claim 1, wherein

$\mathbf{R^1}$ is hydrogen;

$\mathbf{R^2}$ is selected from: $\mathbf{R^4}$-C($\mathbf{R^{5a}R^{5b}}$)- and $\mathbf{R^4}$=C($\mathbf{R^6}$)-;

$\mathbf{R^3}$–X- is selected from methyl and methoxymethyl;

$\mathbf{R^4}$ is selected from phenyl and $C_{3-6}$cycloalkyl, wherein $\mathbf{R^4}$ is optionally substituted by one or two substituents independently selected from $\mathbf{R^7}$;

$R^{5a}$ and $R^{5b}$ are independently selected from hydrogen and fluoro;

$R^6$ is hydrogen;

$R^7$ is independently selected from $C_{1-3}$alkyl, $C_{1-3}$alkoxy, fluoro and chloro;

with the proviso that:

(iii) at least one of $R^{5a}$ and $R^{5b}$ is fluoro;

(iv) when $R^2$ is $R^4$=C($R^6$)- then $R^4$ is $C_{3-6}$cycloalkyl;

or a salt, solvate or pro-drug thereof.

7. A compound of formula (I) as claimed in Claim 6 wherein $R^7$ is unsubstituted; or a salt, solvate or pro-drug thereof.

8. A compound of formula (I) as claimed in Claim 6 wherein both $R^{5a}$ and $R^{5b}$ are fluoro; or a salt, solvate or pro-drug thereof.

9. A compound of formula (I) as claimed in Claim 1, which compound is selected from:

6-{[(3-[(2,2-difluoro-2-phenylethyl)oxy]-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}phenyl)carbonyl]amino}pyridine-3-carboxylic acid;

6-[({3-[(2,2-difluoro-2-phenylethyl)oxy]-5-[(1-methylethyl)oxy]phenyl}carbonyl)amino]pyridine-3-carboxylic acid ;

6-{[(3-[(2-cyclopentylideneethyl)oxy]-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}phenyl)carbonyl]amino}pyridine-3-carboxylic acid; and

6-{[(3-[(2-cyclopentylideneethyl)oxy]-5-[(1-methylethyl)oxy]phenyl}carbonyl)amino]pyridine-3-carboxylic acid;

or a salt, solvate or pro-drug thereof.

10. A pharmaceutical composition comprising a compound of Formula (I) as claimed in any one of Claims 1 to 9, or a salt, solvate or prodrug thereof, together with a pharmaceutically-acceptable diluent or carrier.

11. A compound of Formula (I), as claimed in any one of Claims 1 to 9, or a salt, solvate or prodrug thereof, for use as a medicament.

12. A compound of Formula (I), as claimed in any one of Claims 1 to 9, or a salt, solvate or prodrug thereof, for use in the preparation of a medicament for treatment of a disease mediated through GLK, in particular type 2 diabetes.

13. A method of treating GLK mediated diseases, especially diabetes, by administering an effective amount of a compound of Formula (I), as claimed in any one of Claims 1 to 9, or a salt, solvate or prodrug thereof, to a mammal in need of such treatment.

14. The use of a compound of Formula (I), as claimed in any one of Claims 1 to 9, or salt, solvate or pro-drug thereof, in the preparation of a medicament for use in the combined treatment or prevention of diabetes and obesity.

15. The use of a compound of Formula (I), as claimed in any one of Claims 1 to 9, or salt, solvate or pro-drug thereof, in the preparation of a medicament for use in the treatment or prevention of obesity.

16. A method for the combined treatment of obesity and diabetes by administering an effective amount of a compound of Formula (I), as claimed in any one of Claims 1 to 9, or salt, solvate or pro-drug thereof, to a mammal in need of such treatment.

17. A method for the treatment of obesity by administering an effective amount of a compound of Formula (I), as claimed in any one of Claims 1 to 9, or salt, solvate or pro-drug thereof, to a mammal in need of such treatment.

18. A process for the preparation of a compound of Formula (I) as claimed in Claim 1, a salt, pro-drug or solvate thereof which comprises:
comprises:

(a) reaction of an acid of Formula (IIIa) or activated derivative thereof with a compound of Formula (IIIb),



Formula (IIIa)



Formula (IIIb);

wherein $\mathbf{P^1}$ is hydrogen or a protecting group; or

(b) de-protection of a compound of Formula (IIIc),



Formula (IIIc)

wherein $\mathbf{P^2}$ is a protecting group; or

(c) reaction of a compound of Formula (IIId) with a compound of Formula (IIIe),



Formula (IIId)



Formula (IIIe)

wherein $\mathbf{X^1}$ is a leaving group and $\mathbf{X^2}$ is a hydroxyl group or $\mathbf{X^1}$ is a hydroxyl group and $\mathbf{X^2}$ is a leaving group and wherein $\mathbf{P^1}$ is hydrogen or a protecting group; or

(d) reaction of a compound of Formula (IIIf) with a compound of Formula (IIIg)



Formula (IIIf)



Formula (IIIg)

wherein $X^3$ is a leaving group and $X^4$ is a hydroxyl group or $X^3$ is a hydroxyl group and $X^4$ is a leaving group wherein $P^1$ is hydrogen or a protecting group; or

(e) reaction of a compound of Formula (IIIh) with a compound of Formula (IIIi),



Formula (IIIh)



Formula (IIIi);

wherein $X^5$ is a leaving group and wherein $P^1$ is hydrogen or a protecting group;

and thereafter, if necessary:

i) converting a compound of Formula (I) into another compound of Formula (I);

ii) removing any protecting groups;

iii) forming a salt, pro-drug or solvate thereof.